Division of BioLineRx Ltd.
Latest From Agalimmune Ltd.
Appointments: Eli Lilly, Alexion, Actelion, Polyphor, Constellation, Bone Therapeutics and Allied Minds
This week's roundup includes the announced retirement of Lilly's CFO, high-level appointments by Alexion Pharmaceuticals, Actelion and Constellation, and board elections by Wilson Therapeutics, Bone Therapeutics and Atlantic Healthcare.
Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
BioLineRx buys Agalimmune and its alpha Gal candidate for melanoma and possibly other oncology indications. Japan's Ono signs an R&D agreement with Switzerland's Numab, while Boston biotechs Vedantra and Neon will collaborate on potential cancer vaccines.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- BioLineRx Ltd.
- Senior Management
Damian Marron, PhD, CEO
Graham Griffiths, COO
- Contact Info
6 Arlington St.
London, CA SW1A 1RE
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.